PL2032607T5 - Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi - Google Patents

Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi

Info

Publication number
PL2032607T5
PL2032607T5 PL07726010T PL07726010T PL2032607T5 PL 2032607 T5 PL2032607 T5 PL 2032607T5 PL 07726010 T PL07726010 T PL 07726010T PL 07726010 T PL07726010 T PL 07726010T PL 2032607 T5 PL2032607 T5 PL 2032607T5
Authority
PL
Poland
Prior art keywords
fusion protein
blood coagulation
coagulation factor
proteolytically cleavable
cleavable fusion
Prior art date
Application number
PL07726010T
Other languages
English (en)
Other versions
PL2032607T3 (pl
Inventor
Hubert Metzner
Thomas Weimer
Stefan Schulte
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38430551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2032607(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06012262A external-priority patent/EP1867660A1/en
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL2032607T3 publication Critical patent/PL2032607T3/pl
Publication of PL2032607T5 publication Critical patent/PL2032607T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL07726010T 2006-06-14 2007-06-14 Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi PL2032607T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06012262A EP1867660A1 (en) 2006-06-14 2006-06-14 Proteolytically cleavable fusion protein comprising a blood coagulation factor
US81962006P 2006-07-11 2006-07-11
EP07726010.7A EP2032607B2 (en) 2006-06-14 2007-06-14 Proteolytically cleavable fusion protein comprising a blood coagulation factor
PCT/EP2007/005246 WO2007144173A1 (en) 2006-06-14 2007-06-14 Proteolytically cleavable fusion protein comprising a blood coagulation factor

Publications (2)

Publication Number Publication Date
PL2032607T3 PL2032607T3 (pl) 2014-06-30
PL2032607T5 true PL2032607T5 (pl) 2017-10-31

Family

ID=38430551

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07726010T PL2032607T5 (pl) 2006-06-14 2007-06-14 Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi
PL21162926T PL3896090T3 (pl) 2006-06-14 2007-06-14 Rozszczepialne proteolitycznie białko fuzyjne zawierające czynnik krzepnięcia krwi

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21162926T PL3896090T3 (pl) 2006-06-14 2007-06-14 Rozszczepialne proteolitycznie białko fuzyjne zawierające czynnik krzepnięcia krwi

Country Status (9)

Country Link
EP (2) EP2032607B2 (pl)
JP (1) JP5800458B2 (pl)
KR (1) KR101641899B1 (pl)
AU (1) AU2007260185B2 (pl)
CA (1) CA2655248C (pl)
DK (2) DK2256135T3 (pl)
ES (2) ES2889920T3 (pl)
PL (2) PL2032607T5 (pl)
WO (1) WO2007144173A1 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
WO2011020866A2 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
PL3715356T3 (pl) 2009-12-18 2024-03-11 Csl Limited Sposób oczyszczania polipeptydów
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
MX356527B (es) 2010-07-09 2018-06-01 Bioverativ Therapeutics Inc Polipeptidos de factor ix y metodos para usarlos.
TW201217526A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Chimeric clotting factors
DK2681245T3 (en) * 2011-03-03 2018-08-13 Zymeworks Inc MULTIVALENT HEAT-MULTIMED SCAFFOLD DESIGN AND CONSTRUCTIONS
EP3417881A1 (en) * 2011-10-06 2018-12-26 Hanmi Science Co., Ltd. Blood coagulation factor vii and viia derivatives, conjugates and complexes comprising the same, and use thereof
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US11370827B2 (en) 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
JP6603128B2 (ja) 2012-07-11 2019-11-06 バイオベラティブ セラピューティクス インコーポレイテッド ＸＴＥＮおよびｖｏｎＷｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
AU2013289881B2 (en) 2012-07-13 2018-01-18 Zymeworks Bc Inc. Multivalent heteromultimer scaffold design and constructs
US20150252345A1 (en) 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
WO2014210547A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
MY192481A (en) 2014-01-10 2022-08-23 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
DK3297656T3 (da) 2015-05-22 2020-03-09 CSL Behring Lengnau AG Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
WO2017066653A1 (en) * 2015-10-15 2017-04-20 Woods Hole Oceanographic Institution Compositions and methods for absolute quantification of proteins
BR112018013822A2 (pt) 2016-01-07 2018-12-11 Csl Behring Recombinant Facility Ag ?polipeptídeo modificado, complexo, composição farmacêutica, métodos para tratamento de um distúrbio hemorrágico, para produção de um polipeptídeo e para aumento da meia-vida do fator viii, uso de um polipeptídeo modificado, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira?
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
EP3589329B1 (en) 2017-05-11 2022-10-12 Zentrum für Forschungsförderung in der Pädiatrie GmbH Concept for the treatment of monogenetic disorders
WO2019067766A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
WO2019195055A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
EP3941509A1 (en) 2019-03-19 2022-01-26 CSL Behring Lengnau AG Factor ix variants and uses thereof in therapy
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
MX9700312A (es) * 1994-07-11 1997-07-31 Univ Texas Metodos y composiciones para la coagulacion especifica en vasculatura.
ES2484966T3 (es) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
WO2002004598A2 (en) 2000-07-12 2002-01-17 Immunex Corporation Improvement of cell culture performance by inhibitors of pyruvate dehydrogenase kinase
US7122641B2 (en) 2001-12-21 2006-10-17 Immunex Corporation Methods for purifying protein
EP1572908A4 (en) 2002-02-14 2008-10-22 William J Rutter CHIMERIC MOLECULES FOR ADMINISTERING CLEAVAGE TO A TREATED HOST
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP3552627A1 (en) 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1670931A2 (en) 2003-09-05 2006-06-21 GTC Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life

Also Published As

Publication number Publication date
EP2032607B2 (en) 2017-02-22
ES2910207T3 (es) 2022-05-11
ES2889920T3 (es) 2022-01-14
DK3896090T3 (da) 2022-03-21
PL2032607T3 (pl) 2014-06-30
EP2032607B1 (en) 2014-01-22
EP2032607A1 (en) 2009-03-11
WO2007144173A1 (en) 2007-12-21
DK2256135T3 (da) 2019-06-11
PL3896090T3 (pl) 2022-05-02
AU2007260185A1 (en) 2007-12-21
CA2655248C (en) 2016-02-09
EP3896090A1 (en) 2021-10-20
CA2655248A1 (en) 2007-12-21
EP3896090B1 (en) 2022-01-12
KR101641899B1 (ko) 2016-08-01
AU2007260185B2 (en) 2013-01-31
KR20090023486A (ko) 2009-03-04
JP2009539391A (ja) 2009-11-19
JP5800458B2 (ja) 2015-10-28

Similar Documents

Publication Publication Date Title
PL2032607T5 (pl) Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi
DK2032607T3 (da) Proteolytisk spalteligt fusionsprotein omfattende en blodkoaguleringsfaktor
ZA200901280B (en) Exendin fusion proteins
IL196889A0 (en) Albumin-insulin fusion proteins
IL222924A0 (en) Albumin fusion proteins
IL197580A0 (en) Albumin fusion proteins
PL1830872T3 (pl) Białka fuzyjne
GB0426397D0 (en) Fusion proteins
EP1988927A4 (en) FUSIONS SYNTHETIC ANTIBODY-STRESS PROTEIN
ZA200810677B (en) Fusion proteins, uses thereof and processes for producing same
EP1951862A4 (en) CD40 LIGAND FUSION PROTEIN VACCINE
EP1934372A4 (en) SSB-POLYMERASE HYBRID PROTEINS
IL189246A0 (en) Albumin fusion proteins
IL197221A (en) Method for cleaning up protein
EP1858546A4 (en) MODIFIED TRANSFERRINFUSION PROTEINS
GB0519965D0 (en) Joint fusion peg
EP2007884A4 (en) ENZYMATIC FUSION PROTEINS AND THEIR USE
EP1996186A4 (en) PROCESS FOR THE PREPARATION OF RECOMBINANT HUMAN THROMBIN AND FIBRINOGEN
ATE412389T1 (de) Chirurgisches system mit integrierten pneumatischen übergangsstücken
AP2777A (en) Fixed-dose syringe with limited aspiration
ZA200801224B (en) Albumin fusion proteins
GB0604938D0 (en) Proteins, nucleic acids and medicaments
ZA200708576B (en) Blood pressure lowering protein hydrolysates
GB0625681D0 (en) A joint fixator
ZA200808656B (en) Enzyme fusion proteins and their use